Sign Out
Heterozygous familial hypercholesterolaemia
Child: Adjunct to diet, alone or in combination with statin and/or other lipid-lowering therapies: ≥10 years 140 mg once every 2 weeks or 420 mg once monthly. Treatment recommendations may vary between countries (refer to specific product guidelines).
Subcutaneous
Heterozygous familial hypercholesterolaemia, Mixed dyslipidaemia, Nonfamilial hypercholesterolaemia
Adult: Adjunct to diet, alone or in combination with statin and/or other lipid-lowering therapies: 140 mg once every 2 weeks or 420 mg once monthly. Treatment recommendations may vary between countries (refer to specific product guidelines).
Subcutaneous
Homozygous familial hypercholesterolaemia
Adult: In combination with other lipid-lowering therapies: Initially, 420 mg once monthly. After 12 weeks, dose may be increased to 420 mg once every 2 weeks if necessary. Patients on apheresis: 420 mg once every 2 weeks.
Child: In combination with other lipid-lowering therapies: ≥10 years Same as adult dose. Treatment recommendations may vary between countries (refer to specific product guidelines).
Child: In combination with other lipid-lowering therapies: ≥10 years Same as adult dose. Treatment recommendations may vary between countries (refer to specific product guidelines).
Subcutaneous
Cardiovascular risk reduction
Adult: To reduce the risk of CV events (e.g. MI, stroke, unstable angina requiring hospitalisation, coronary revascularisation) by decreasing LDL-C levels in patients with established atherosclerotic CV disease: Alone or in combination with the maximally tolerated statin dose and/or other lipid-lowering therapies: 140 mg once every 2 weeks or 420 mg once monthly. Treatment recommendations may vary between countries (refer to specific product guidelines).
